Advances in the Targeted Drug Delivery System for Renal Fibrosis Authors: Yan-Yan Zheng, Ji-Fu Hao, Jin-Ye Liu, Shu-Yu Wang, Xiao-Dong Mu, Hu-Lin Jiang, Yu-Jing He Published: 2026 ABSTRACT AbstractRenal fibrosis represents the ultimate outcome of almost all chronic kidney diseases (CKD), and is the primary cause of end-stage renal disease, making it a serious global health burden. Despite numerous preclinical drugs demonstrating potential in the treatment of renal fibrosis, the majority fail to fulfill the stringent criteria for clinical applications. Key hurdles in renal fibrosis therapy not only involve intricate signaling networks and fibrosis-perpetuating microenvironments, complex renal structures, and pathological barriers, but also restrict drug delivery to lesions. Therefore, recent delivery system focused on co-delivering multiple drugs via nanoplatforms and functionalized with targeting ligands. These systems enable precise drug delivery to key effector cells in fibrosis (eg, myofibroblasts and tubular epithelial cells), thereby achieving targeted and highly effective therapy. This review summarizes the signaling pathways of renal fibrosis using the concept of the fibrosis niche and critically evaluates both drug delivery barriers and emerging targeted drug delivery system (TDDS). Furthermore, the potential challenges and future directions of TDDS for reversing renal fibrosis are discussed with the aim of providing guidance for the development of new therapeutic strategies. Introduction Chronic kidney disease (CKD) is defined as chronic renal structural damage and dysfunction caused by various reasons, with a glomerular filtration rate (GFR) below 60 mL/min⋅1.73 m2 and a duration of at least 3 months.1,2 According to statistics, the global prevalence of CKD is 10~14%, which has become a serious threat to human life.3 Renal fibrosis can be defined as excessive repair of kidney damage, which is an important process and common pathological state in the progression of CKD to end stage renal disease (ESRD).4,5 Over time, numerous studies have meticulously elucidated the cellular and molecular mechanisms of renal fibrosis.6 Currently, it is widely believed that renal fibrosis is not a static and uniform “scar”, but a continuous process that occurs within the “fibrotic niche” (Figure 1).7 Its characteristics mainly involve the inflammatory cells infiltration, myofibroblast activation, extracellular matrix (ECM) dysregulation, cell matrix-interaction, renal tubular atrophy and glomerulosclerosis, and microvascular sparsity.8 They together constitute a set of fibrogenesis events, ultimately leading to the destruction of renal parenchyma and loss of renal function.9 Figure 1The development of renal fibrosis. Glomerular hypertrophy leads to a decrease in filtration rate, which is closely related to renal tubular injury. When the pressure of the glomerulus increases and leads to glomerular hypertrophy, the pressure on the glomerular blood vessel wall will also increase. At this time, podocyte injury promotes the loss of nephrons, which is the main reason for the decrease in glomerular filtration rate. Cells are damaged by excessive endocytosis of proteins and fatty acids, leading to the release of inflammatory factors, which then transform into myofibroblasts and release a large amount of extracellular matrix.Diagram of renal fibrosis showing podocyte detachment, hypertrophy and nephron loss with cell types labeled.The diagram illustrates the process of renal fibrosis. It shows podocyte detachment and hypertrophy leading to increased capillary wall stress and intraglomerular pressure. This results in the loss of nephrons and a decrease in glomerular filtration rate. The diagram also depicts the release of pro-inflammatory cytokines and the transformation of cells into myofibroblasts. Various cell types are labeled, including tubular cells, fibroblasts, pericytes, macrophages, podocytes, epithelial cells, mesangial cells and endothelial cells. The diagram highlights the role of TGF beta, Notch, Wnts, Hh and ECM in the process.Abbreviations: TGFβ, Transforming growth factor; Notch, Notch signaling; Wnts, Wnts signaling; Hh, Hedgehog signaling; ECM, Extracellular matrix. The development of renal fibrosis. Glomerular hypertrophy leads to a decrease in filtration rate, which is closely related to renal tubular injury. When the pressure of the glomerulus increases and leads to glomerular hypertrophy, the pressure on the glomerular blood vessel wall will also increase. At this time, podocyte injury promotes the loss of nephrons, which is the main reason for the decrease in glomerular filtration rate. Cells are damaged by excessive endocytosis of proteins and fatty acids, leading to the release of inflammatory factors, which then transform into myofibroblasts and release a large amount of extracellular matrix. Drug therapy is crucial to delay and reverse renal fibrosis. Clinically established foundational medications for renal fibrosis (eg, renin-angiotensin system (RAS) blockers and sodium/glucose cotransporter 2 (SGLT2) inhibitors) primarily target secondary pathogenic pathways (eg, hemodynamic or metabolic dysregulation) rather than directly inhibiting core fibrotic mechanisms (eg, TGF-β/Smad or Wnt/β-catenin signaling).10,11 This indirect action may limit their efficacy in advanced fibrosis. Furthermore, the drugs in development are focused on recognized key regulatory nodes in the molecular mechanisms of renal fibrosis, such as transforming growth factor 1 (TGF-β1), Notch, Wnt, and Hedgehog.12 The FDA approved pirfenidone for the treatment of idiopathic pulmonary fibrosis through inhibition of the TGF-β1 signaling pathway has entered Phase II clinical trials for the treatment of renal fibrosis.13 Besides, preclinical studies have shown that natural products such as salvianolic acid B and curcumin exhibit excellent anti-fibrotic activity.14,15 However, these drugs have serious limitations for the treatment of renal fibrosis. Most drugs cannot accumulate in fibrotic kidneys owing to metabolic effects, complex renal structures, and pathological barriers.16 A limited amount of drugs reaching the lesion is forced to use higher doses of medication but cause toxic side effects. Moreover, the complex molecular mechanisms underlying renal fibrosis render single-drug approaches ineffective for complete treatment. And the continuous activation of signaling pathways without effective intervention will lead to the deterioration of the pathological microenvironment, exacerbate the process of renal fibrosis, and form a vicious cycle.17 Therefore, increasing drug enrichment at the site of fibrosis, achieving synergistic regulation of fibrosis signaling pathways, and breaking the vicious cycle of pathological microenvironment are key means to improve the treatment efficiency of renal fibrosis.18 Targeted drug delivery systems (TDDS) have emerged as novel method for overcoming these limitations. Specific nanocarriers (liposomes, chitosan nanoparticles, extracellular vesicles, etc.) can accurately deliver drugs to target cells, thereby improving therapeutic efficacy and reducing drug interference in healthy renal parenchymal cells.19,20 In this review, we discuss the intrinsic relationship between CKD and renal fibrosis and provide a basis for renal fibrosis treatment. In addition, we present the relevant cells and signaling pathways in renal fibrosis through the concept of “niche,” and critically summarize current therapeutic drugs targeting key molecular pathways in renal fibrosis. Finally, we analyzed the main drug delivery barriers, including the systemic circulation barrier, glomerular filtration, renal tubular resorption and clearance, and ECM deposition, along with a review of existing TDDS. A deeper understanding of the pathological mechanisms and progression of renal fibrosis will enable TDDS to overcome drug delivery barriers and enhance targeting efficacy, thereby providing critical guidance for clinical management of renal fibrosis. The Niche of Renal Fibrosis The renal fibrosis niche can be considered as a unique tissue microenvironment caused by renal injury, which has become an innovative method for describing the mechanism of renal fibrosis. The composition and content of the renal fibrosis niche undergoes changes during the evolution of injury repair and tissue remodeling, which are coordinated by a de novo ECM network. The elements that constitute the renal fibrotic niche mainly include resident cells in the kidney, ECM network, soluble factors, and extracellular vesicles listed in below parts.17 Sources of Myofibroblasts in Renal Fibrosis Myofibroblasts are activated to repair kidney injury, which can be recognized by a rough endoplasmic reticulum and Golgi apparatus, mainly in spindle or star shapes, but do not exist in a healthy state. After the wound subsided, cells underwent apoptosis. Myofibroblasts are capable of expressing most ECM genes and are the “culprit” for the excessive synthesis, deposition, and remodeling of extracellular matrix proteins in renal fibrosis.21,22 Clarifying the origin of myofibroblasts is crucial for understanding their heterogeneous characteristics and behavior, which may provide a basis for finding reliable and effective anti renal fibrosis methods. Recently, Christoph et al addressed this issue by conducting a comprehensive analysis of 87362 renal cortical cells in 13 hypertensive patients with CKD caused by renal sclerosis.21 The main sources of myofibroblasts include local fibroblast, pericytes, and macrophage proliferation, EMT, endothelial mesenchymal transition (EndoMT), and bone marrow-derived fibroblasts.23–25 Fibroblast In a healthy state, fibroblasts are located in the stroma between capillaries and epithelium, which is crucial for maintaining stromal homeostasis. However, in pathological conditions, fibroblasts differentiate into myofibroblasts under the induction of inflammatory factors, growth factors, hypoxia, and mechanical forces.26 In addition, the fibrotic niche also plays a role in fibroblast activation, determining the discrete position of fibroblasts.27 Activated fibroblasts synthesize more ECM with altered characteristics, and the synthesis of new ECM in turn promotes the activation of existing fibroblasts.28,29 Resident fibroblasts are the main precursors of renal myofibroblasts, and studies have shown that 50% of renal myofibroblasts originate from resident fibroblasts during renal fibrosis.30 Pericyte In a healthy state, pericytes from different sources have different functions, such as wrapping capillaries and microvasculature to regulate angiogenesis, stabilizing the microvascular network, and controlling blood flow through vascular contraction; specialized perirenal cells of mesangial cells provide physical support for glomerular capillaries, and the subset of periarterial cells near the glomerulus controls local blood pressure in the glomerulus through contraction and affects systemic blood pressure by secreting renin.31–33 However, in pathological conditions, pericyte myofibroblast transformation (PMT) may occur.34 Similarly, PMT is also regulated by many cytokines. The recognized definition of Pericytes are a type of cell that come into contact with the endothelium and are embedded in the vascular basement membrane. They transform into myofibroblasts and are no longer embedded in the vascular basement membrane. However, the difference in surface markers between pericytes and myofibroblasts is not significant, while surface markers of myofibroblasts α-Smooth actin can also be detected on the surface of pericytes.35 The renin angiotensin system (RAS) plays an important role in renal fibrosis, and Brunskil et al demonstrated the potential relationship between renin expressing cells and pericytes through microarray studies using fluorescence activated cell sorting (FACS) purified mouse renin expressing cells.36 Macrophage The role of macrophages in renal fibrosis has always been believed to indirectly promote renal fibrosis by secreting cytokines to promote fibroblast proliferation.37 Recently, it has been discovered that the transition from macrophages to myofibroblasts (MMT) is another source of myofibroblasts.38 Under the influence of inflammatory microenvironments, macrophages can polarize into either pro-inflammatory phenotype (M1) or anti-inflammatory phenotype (M2). M2 macrophages can secrete interleukin-10 and TGF-β1 to stimulate proliferation of myofibroblasts.23 And according to cell tracing in a unilateral ureteral obstruction (UUO) mouse model, 90% of macrophages that undergo MMT in the fibrotic mouse kidneys originate from bone marrow.39 LeBleu et al used in bone marrow transplantation experiments α-SMA red fluorescent protein mice demonstrate that bone marrow-derived cells contribute approximately 35% to renal myofibroblasts.30 Additionally, studies have shown that approximately 70% of type I collagen cells are derived from bone marrow monocytes/macrophages, supporting the notion that myofibroblasts may originate from sources outside the renal system.30 The Main Components in the ECM Network of Renal Fibrosis The extracellular matrix (ECM) is an extracellular matrix that provides mechanical support to cells and maintains tissue homeostasis.40 ECM network is a highly dynamic 3D physical scaffold that is mainly divided into four categories: matricellular proteins (such as tenascin C, connective tissue growth factor, fibrilin 1), structural ECM proteins (such as collagen, fibronectin, and elastin), glycosaminoglycan (such as hyaluronic acid), and matrix-modifying proteins (such as matrix metalloproteinases).17,41–43 Among them, matricellular proteins are typical components of fibrotic niche; structural ECM protein deposition is a marker of tissue fibrosis; proteoglycans are the main components of ECM; and matrix-modifying proteins are mainly involved in ECM remodeling. Under normal circumstances, ECM regulates cell proliferation, migration, and differentiation through interactions with cells, and cells also release related proteins responsible for ECM degradation.44,45 ECM remodeling and degradation imbalance lead to deposition, which is an important process in the occurrence of renal fibrosis and an important part of the renal fibrosis niche.46 Compared to infiltrating inflammatory cells, extracellular vesicles, or metabolites that easily diffuse according to concentration gradients, the deposition site of the ECM network is relatively stable and can form a clear regional contour, which is consistent with the formation of niches. Therefore, the ECM can be considered the anchor point of the fibrotic niche.17 Tenascin C Tenascin C (TNC) is a large oligosaccharide protein considered a key component of the renal fibrosis niche. Under normal physiological conditions, TNC is almost undetectable in the kidneys, and is produced by interstitial fibroblasts during the early stages of kidney injury. In the late stage of CKD, macrophages and even renal tubular epithelial cells can express TNC.27 As a matrix cell protein, TNC is not a mandatory structural element in ECM, but it can bind to ECM structural proteins and cell surface receptors (such as integrins) to activate its downstream pathways, thereby regulating cell adhesion, diffusion, migration, and proliferation in a cell type and environment dependent manner.47–50 Research has shown that during the process of renal fibrosis, TNC provides a favorable microenvironment for the proliferation of fibroblasts. The molecular mechanism by which TNC promotes fibroblast proliferation seems to be related to its activation of the integrin/focal adhesion kinase (FAK)/mitogen-activated protein kinase (MAPK) cascade reaction.27 In addition, TNC triggers EMT by continuously activating the integrin αvβ6/FAK/ERK-1/2 signaling cascade, thereby damaging renal tubular integrity.41 Collagen Collagen is the main structural protein of ECM, composed of two forms: fibrillar (collagen I–III, V, XI, XXIV and XXVII) and non-fibrillar.51 Collagen fiberils provide tensile strength to ECM, limiting tissue expansion.44 During the process of physiological tissue repair, aggregated type I collagen can limit cell proliferation by connecting α2β1 integrins.52 During lung injury repair, aggregated collagen typically terminates collagen deposition in fibroblasts and activates cell apoptosis.53 But when cells transform into fibrotic forms, they no longer respond to collagen signals that terminate fibrosis.45 Over 30 years ago, Kuhn and McDonald demonstrated through the use of type I collagen specific monoclonal antibodies that the core of myofibroblasts is a site for active ECM deposition.54 The mechanism of excessive collagen deposition in myofibroblasts involves inhibition of miR-29, which is the main negative regulatory molecule of the ECM gene.55 Therefore, once miR-29 is inhibited, the fibrotic ECM will establish a positive pro-fibrotic feedback loop, stimulating further ECM production. Hyaluronic Acid Hyaluronic acid (HA) is a naturally occurring high molecular weight glycosaminoglycan in human tissues and is composed of polymerized glucuronic acid and N-acetylglucosamine disaccharides, which are treated with glucuronic acid β (1→3) bonds and hexosamine β (1→4) bond coupling.56 HA exists in soluble form in ECM and covalently bonds with various proteins. Research has confirmed that hyaluronic acid and its derivatives have good biodegradability (mainly driven by hyaluronidase) and biocompatibility, which can promote rapid healing of damaged tissues and support cell survival, proliferation, and differentiation.57 In fibrotic kidneys, the CD44 receptor on the surface of fibroblasts and myofibroblasts is one of the natural receptors for HA. Studies have shown that the accumulation of endogenous HA can promote the phenotypic transformation of fibroblasts driven by TGF-β1 into myofibroblasts.58 Matrix Metalloproteinases Matrix metalloproteinases (MMPs) belong to a family of multidomain zinc-dependent endopeptidases consisting of 23 members.59 They can degrade all types of ECM components and are crucial for maintaining ECM homeostasis and remodeling.17 Under the regulation of tissue inhibitors of matrix metalloproteinases (TIMP), MMPs have low activity in healthy tissues and are significantly upregulated in fibrotic kidneys.17,60 At first glance, the increase in MMPs content can solve the problem of excessive ECM accumulation, which seems to be beneficial for addressing renal fibrosis. Overall, some MMPs have anti-fibrotic effects, while others promote the development of fibrosis, which requires comprehensive consideration of cell proliferation, immunity, inflammation regulation, and degradation products of the ECM.61 Signal Pathways in Renal Fibrosis Activation of signaling pathways is necessary for the repair of damaged kidney tissue; however, sustained activation can lead to excessive cellular responses and exacerbate the development of renal fibrosis. The regulatory pathways in renal fibrosis include TGF-β1/Smads, Notch, Wnt, and Hedgehog, among which TGF-β1/Smads are considered the main regulatory pathways for the occurrence of renal fibrosis.12,62 TGF-β1/Smads Signal Pathway TGF-β1/Smad is a multifunctional secreted peptide-growth factor. TGF-β1 in this family member is considered a key driving factor for renal fibrosis, expressed in endothelial cells, hematopoietic cells, and connective tissue cells.63 TGF-β1 secreted outside the cell binds to the transforming growth factor β1 receptor (TGFR) on the cell membrane and exerts its effect. TGF-β1 is significantly upregulated in fibrotic kidneys and has the ability to affect cell growth, apoptosis, and differentiation; increase ECM production; and maintain fibroblast activity.64 The Smad family proteins are crucial for TGF-β1 mediated renal fibrosis. TGF-β1 exerts its biological effects by activating downstream mediators including Smad2 and Smad3, while being negatively regulated by Smad7 expression The TGF-β1 cascade reaction is composed of a ternary signaling complex. When TGF-β1 interacts with TGFR2 (TGF-β receptor 2), this complex is activated, and TGFR2 phosphorylates TGFR1, which in turn phosphorylates the cytoplasmic mediators Smad1 and Smad3, and forms heterotrimeric complexes with Smad4 translocated to the nucleus, regulating downstream gene transcription.21,65 The activation of the TGF-β1/Smad signaling pathway can trigger ECM deposition, as well as the generation and activation of local myofibroblasts, thereby promoting the development of renal fibrosis62 (Figure 2). Figure 2Overview of TGF-β1/Smads signaling pathway in renal fibrosis. TGF-β1 is released from the latency associated peptide (LAP)- latent TGF-β1 binding protein (LTBP) complex and binds to TGF-β receptor 2 (TGFR2), then recruits and activates TGFR1. Then active TGFR1 phosphorylates Smad2 and Smad3, which form complexes with Smad4 and translocates to the nucleus. The Smad3 component of this complex directly binds to the gene promoter, inducing transcription of pro-fibrotic molecules. Blue arrows represent positive signal transduction, green arrows represent enzymatically cleave.TGF-beta1/Smads pathway in renal fibrosis: activation, phosphorylation, transcription regulation.The image illustrates the TGF-beta1/Smads signaling pathway in renal fibrosis. TGF-beta1 is released from the latent TGF-beta1 binding protein complex through cleavage. It binds to TGF-beta receptor 2, recruiting and activating TGF-beta receptor 1. This activation leads to the phosphorylation of Smad2 and Smad3, which form complexes with Smad4 and translocate to the nucleus. In the nucleus, these complexes bind to gene promoters, inducing transcription of pro-fibrotic molecules such as alpha-SMA, collagens and fibronectin. The pathway also shows extracellular matrix deposition and myofibroblast activation. Smad7 negatively regulates this process. The diagram includes terms like EMT, PMT, MMT and EndoMT, indicating different transition processes. Overview of TGF-β1/Smads signaling pathway in renal fibrosis. TGF-β1 is released from the latency associated peptide (LAP)- latent TGF-β1 binding protein (LTBP) complex and binds to TGF-β receptor 2 (TGFR2), then recruits and activates TGFR1. Then active TGFR1 phosphorylates Smad2 and Smad3, which form complexes with Smad4 and translocates to the nucleus. The Smad3 component of this complex directly binds to the gene promoter, inducing transcription of pro-fibrotic molecules. Blue arrows represent positive signal transduction, green arrows represent enzymatically cleave. Notch Signal Pathway In CKD, Notch signaling is upregulated in tubular epithelial cells. Elevated expression of Notch receptors correlates with the activation of pro-fibrotic pathways and pathological accumulation of ECM. In vitro, upregulation of Notch receptors in tubular epithelial cells drives their transition toward activated myofibroblasts, a process associated with enhanced cell proliferation and suppression of renal tubular epithelial differentiation markers. Notch1 lysis in epithelial renal tubular cells induces cell-specific expression, leading to increased epithelial cell proliferation and dedifferentiation of the renal tubular epithelium.66 Notch3 may be a key subtype associated with renal fibrosis. Notch3 gene deletion protects mice from UUO-induced renal tubulointerstitial fibrosis.67 Furthermore, from the perspective of signal pathway crosstalk, increased expression of Notch in the renal tubular epithelium is associated with elevated TGF-β1 levels.12 Wnt Signal Pathways Wnt proteins belong to the family of secreted lipid-modified glycoproteins. With 19 known Wnt ligands and over 15 receptors or co-receptors identified, Wnt signaling involves highly complex molecular interactions that remain incompletely understood.68 Research has shown that Wnt primarily relies on classical β-catenin dependent pathway plays a role in renal fibrosis.69 Research has shown that transient activation of the Wnt/β-catenin pathway promotes tissue repair through epithelial proliferation, while sustained activation promotes renal aging and fibrosis by inducing cellular senescence.70 Wnt4 expressed by myofibroblasts can induce the proliferation and transformation of resident fibroblasts into myofibroblasts. Wnt/β-catenin signal transduction in pericytes and interstitial fibroblasts results in spontaneous differentiation of myofibroblasts, which is a related step in fibrosis development.12 Hedgehog Signal Pathway Hedgehog (Hh) signaling is crucial for cell growth, differentiation, and organ development in mammals.71 Abnormal Hh signaling can lead to organ developmental abnormalities, cancer, fibrosis, and other diseases.72 There are three types of Hh ligands in the human body: Sonic Hedgehog (Shh), Indian Hedgehog (Ihh) and Desert Hedgehog (Dhh), with Shh being the most extensively studied.73 Activation of Shh signaling contributes to renal fibrosis by driving phenotypic transition of tubular epithelial cells toward a pro-fibrotic, mesenchymal-like state. In addition, Shh promotes the proliferation of pericytes and myofibroblasts. Beyond its direct pro-fibrotic effects, Shh signaling promotes renal fibrosis via dynamic crosstalk with key pathways such as TGF-β, Wnt, and Notch.73 Therapeutic Drugs for Renal Fibrosis Although drug therapy, dialysis, and kidney transplantation are commonly used for renal fibrosis, drug therapy remains the first-line approach for early to moderate stages because of its convenience and cost-effectiveness, whereas dialysis and transplantation are reserved for end-stage renal failure. The current standard clinical therapies primarily delay renal fibrosis by blocking angiotensin II receptors, decreasing proteinuria, and reducing intraglomerular hypertension. Furthermore, most drug treatments in preclinical research mainly reverse renal fibrosis by inhibiting the excessive proliferation of myofibroblasts, decreasing the excessive deposition of ECM, and regulating programmed cell death of myofibroblasts. Compounds and natural product monomers are the primary sources of therapeutic drugs for renal fibrosis. In addition, microRNA (miRNA) or small interfering RNA (siRNA) also plays an important role in the treatment of renal fibrosis (eg miRNA-29, miRNA-21 sponge, BMP7 plasmid, COX2 siRNA, TGFB1 siRNA). Chemical Drugs Used for the Treatment of Renal Fibrosis Chemical drugs which can slow down CKD and delay the process of renal fibrosis can be roughly divided into the following categories: renin angiotensin system (RAS) blockers (such as captopril), sodium-dependent glucose transporters 2 (SGLT2) inhibitors (such as dapagliflozin), mineralocorticoid receptor (MR) antagonists (such as finerenone), glucagon like peptide-1 (GLP-1) receptor agonists (such as efpeglenatide), endothelin-1 (ET-1) blockers (such as atrazostan) and vasopressin V2 receptor antagonists (such as tofapertan).74–79 In addition, as an FDA approved therapeutic drug for pulmonary fibrosis, pirfenidone has entered phase II clinical trials for the treatment of renal fibrosis.13 The ferroptosis inhibitor Liproxstatin-1 can alleviate renal fibrosis induced by unilateral ureteral obstruction by inhibiting ferroptosis in renal tubular epithelial cells.80 Ginkgolide B alleviates oxidative stress and ferroptosis by inhibiting GPX4 ubiquitination to treat diabetic nephropathy.81 RAS Blockers RAS inhibitors are the main therapeutic drugs for CKD and play an important role in reducing vascular pressure and improving the vascular endothelium. ACEIs can be divided into two categories: angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs). Captopril, enalapril, benazepril are all ACEIs while telmisartan and valsartan belong to ARB.74 Compared to ARB, ACEI has a wider range of applications. As early as 1993, Lewis et al found that captopril treatment could delay the rate of renal function loss in patients with DN compared with placebo treatment.82 In 2007, Shirazi et al demonstrated through research that captopril can intervene in renal interstitial fibrosis after urethral obstruction.83 In recent years, combining ACEI with other drugs for renal protection therapy has become a new strategy.84,85 SGLT2 Inhibitors SGLT2 is expressed in the S1 and S2 segments of the proximal renal tubules and plays an important role in the reabsorption of glucose filtered out by the glomerulus.86 Studies have shown that SGLT2 inhibitors can reduce renal ischemia/reperfusion or cyclosporin- and streptozotocin-induced renal fibrosis in the clinical application of diabetes and non-diabetic CKD. In 2018, Zhang et al demonstrated that luseogliflozin can alleviate renal capillary injury and fibrosis in mice after renal injury through a vascular endothelial growth factor-dependent pathway.87 In 2020, Li et al found that engagliflozin exerts renal protective effects by inhibiting EMT and proximal tubular abnormal glycolysis.88 MR Antagonists Angiotensin can lead to an increase in the release of aldosterone from the mineralocorticoid family, which directly regulates the expression of fibrosis related molecule plasminogen activator inhibitor-1 (PAI-1).89 Previous studies have shown that the combination of MR antagonists and RAS blockers can further reduce proteinuria in CKD patients.90 However, spironolactone and epinephrine increase the risk of hyperkalemia in CKD patients.91,92 Finerenone is a novel non-steroidal MR antagonist with higher receptor affinity, studied by Bayer in the United States, and its incidence of hyperkalemia is lower than that of spironolactone.93,94 In 2021, Finerenone (Kerendia) was FDA-approved for the treatment of kidney disease. Natural Products Used for the Treatment of Renal Fibrosis Natural products are precious sources for new drug discovery and clinical use, with a long history and abundant sources, and play an important role in the treatment of various diseases. In recent years, the mechanism of action of many natural products in the treatment of kidney related diseases has been explored, proving that they can effectively improve renal fibrosis.95 These natural products can exert therapeutic effects on renal fibrosis by acting on multiple targets or regulating multiple signaling pathways. In addition to prototype drugs, structural modifications for the treatment of renal fibrosis have become a new strategy in recent years. The modified drug will not alter its pharmacological activity, but will improve its dissolution behavior or targeting properties. At present, it has been found that they mainly include flavonoids, anthraquinone, alkaloids, phenols, glycosides, terpenes, etc.5,96 Phenols Phenolic compounds are widely present in nature and contain aromatic odors. They are widely expressed in plants belonging to the families Rosaceae, Asteraceae, and Lamiaceae. Phenolic compounds have multiple pharmacological activities, including free-radical scavenging, antioxidant, anti-inflammatory, and antitumor effects (Table 1). Salvianolic acid B, curcumin, resveratrol, and catechin-3-gallate have been shown to have anti renal fibrosis effects. Salvianolic acid, an extract of Salvia miltiorrhiza, can promote autophagy by activating the Silent Information Regulatory Factor (SIRT1) or inhibiting mammalian target of rapamycin (mTOR) signaling, reduce the expression level of EMT-related proteins, and significantly inhibit renal fibrosis.97 In addition, Sal B can exert anti-fibrosis effects by inhibiting various signaling pathways, such as TGF-β1/Smad, human platelet-derived growth factor and its receptors (PDGF-C/PDGFR)-α, and the acetylheparanase/multi-ligand proteoglycan axis (HPSE/SDC1) signaling pathway.97–99 Curcumin is an acidic polyphenol extracted from turmeric. Studies have shown that it can target TGF-β1/Smad, peroxisome proliferator-activated receptor-γ (PPAR-γ), mitogen-activated protein kinase/extracellular regulated protein kinase (MAPK/ERK), Wnt, Nrf2 (nuclear factor E2-related factor 2), Klotho, phosphorylated mTOR protein, and other signaling pathways to exert its anti-fibrotic activity.100–105 In addition, curcumin can inhibit the EMT process through the PPAR-γ pathway, inhibit ECM generation by inhibiting Wnt, and reduce oxidative stress through Nrf2.100,104,105 Table 1Phenols with Improved Renal Fibrosis FunctionActive ConstituentsStructural FormsMechanismsReferencesSalvianolic acid BPolycyclic aromatic with phenyl, nitrogen rings, carbonyl, methoxy and hydroxyl groups.Inhibiting TGF-β1/Smad, PDGF-C/PDGFR-α, Regulating HPSE/SDC1axisActivating SIRT1, miR-106b-25[97–99,106]Salvianolic acid A2D skeletal formula of a tri-benzene polyphenol with an ester and two carbonyl groups.Inhibiting NF-κB, p38 MAPK, PDGF-C/PDGFR-α[98,107]CurcuminLine-angle formula of a symmetric diaryl chain with two carbonyls and ring methoxy and hydroxyl groups.Inhibiting TGF-β/PPARγ, Klotho, Akt/mTOR, Regulating Wnt, Activating Nrf2-Keap1[100–105,108]PolydatinA two-dimensional skeletal formula of a substituted benzene linked to a substituted phenyl by an alkene chain.Inhibiting YAP, Regulating Cx32- Nox4, Activating Nrf2, SIRT1[109–112]PterostilbeneSkeletal formula of a hydroxyl phenyl linked by C H equals C H to a trimethoxy phenyl ring.Inhibiting TGF-β1/Smad, Regulating CXCL10[113–116]ResveratrolLine-angle formula of two benzene rings linked by carbon double bond chain, with three hydroxyl groups.Inhibiting hedgehog, TGF-β1/Smad, Regulating AMPK/NOX4/ROS, Upregulating Klotho[115–117]HonokiolLine angle formula of a two ring structure with two hydroxyl groups and two alkene side chains.Activating SIRT3 and Regulating NF-κB/TGF-β1/Smad[118] Table 1Phenols with Improved Renal Fibrosis FunctionActive ConstituentsStructural FormsMechanismsReferencesSalvianolic acid BPolycyclic aromatic with phenyl, nitrogen rings, carbonyl, methoxy and hydroxyl groups.Inhibiting TGF-β1/Smad, PDGF-C/PDGFR-α, Regulating HPSE/SDC1axisActivating SIRT1, miR-106b-25[97–99,106]Salvianolic acid A2D skeletal formula of a tri-benzene polyphenol with an ester and two carbonyl groups.Inhibiting NF-κB, p38 MAPK, PDGF-C/PDGFR-α[98,107]CurcuminLine-angle formula of a symmetric diaryl chain with two carbonyls and ring methoxy and hydroxyl groups.Inhibiting TGF-β/PPARγ, Klotho, Akt/mTOR, Regulating Wnt, Activating Nrf2-Keap1[100–105,108]PolydatinA two-dimensional skeletal formula of a substituted benzene linked to a substituted phenyl by an alkene chain.Inhibiting YAP, Regulating Cx32- Nox4, Activating Nrf2, SIRT1[109–112]PterostilbeneSkeletal formula of a hydroxyl phenyl linked by C H equals C H to a trimethoxy phenyl ring.Inhibiting TGF-β1/Smad, Regulating CXCL10[113–116]ResveratrolLine-angle formula of two benzene rings linked by carbon double bond chain, with three hydroxyl groups.Inhibiting hedgehog, TGF-β1/Smad, Regulating AMPK/NOX4/ROS, Upregulating Klotho[115–117]HonokiolLine angle formula of a two ring structure with two hydroxyl groups and two alkene side chains.Activating SIRT3 and Regulating NF-κB/TGF-β1/Smad[118] Phenols with Improved Renal Fibrosis Function Alkaloids Alkaloids are a class of nitrogen-containing compounds that are widely present in plants, and generally have complex cyclic structures. Alkaloids used in traditional Chinese medicine generally have good anti-inflammatory and antioxidant effects, which are the main mechanisms through which they improve renal fibrosis (Table 2). They mainly exist in plants, such as the poppy, ephedraceae, and rapeseed families. Berberine is the most commonly used alkaloid in the treatment of renal fibrosis. They can act on different signaling pathways to exert their effects. In terms of antioxidant activity, berberine can upregulate the content of the antioxidant central factor, nuclear factor erythroid 2 related factor 2 (Nrf2), thereby downregulating the TGF-β/Smad signaling pathway and inhibiting the EMT process.119 In terms of anti-inflammatory effects, berberine can downregulate the expression of nuclear factor-κB (NF-κB) in the kidneys.120 In addition, it can also inhibit the inflammasome NLRP3.121 Oxymatrine flavescens and sinomenine have also been proven to have anti renal fibrosis effects. Research has shown that oxymatrine flavescens can upregulate the expression of TGF-β1/Smad negative regulatory factor nuclear transcriptional co-repressor protein SnoN, thereby inhibiting the TGF-β1/Smad signaling pathway.122 Sinomenine can reduce the expression level of autophagy flux.123 Table 2Alkaloids with Improved Renal Fibrosis FunctionActive ConstituentsStructural FormsMechanismsReferencesBerberineLine-angle skeletal formula of a fused polycyclic ring system with two methoxy groups and N plus.Inhibiting TGF-β/Smad, NF-κB, Notch/snail, Suppressing the NLRP3 inflammasome, Activating RhoA/ROCK[119–121,124,125]Matrine2D line-bond diagram of a fused three-ring system with two N atoms and one C double bond O group.Decreasing TIMP-1 and FN, and increasing MMP-3[126]OxymatrineLine-angle skeletal structure of a fused three-ring system with two nitrogens, one carbonyl and N plus.Upregulating SnoN and inhibiting TGF-β1/Smad[122]SinomenineLine-angle structure of a fused-ring molecule with hydroxyl, methoxy, carbonyl and tertiary amine groups.Inhibiting autophagy, Activating Nrf2 and inhibiting TGF-β[123,127]ColchicineUnlabeled skeletal structure of a fused four-ring polycyclic compound with methoxy and multiple carbonyl groups.Inactivating RhoA[128]CaffeineA two-dimensional line-bond structure of a fused six-membered and five-membered ring with four N and two C O.Activating Nrf2 signaling and suppressing Snail1[129]Evodiamine2D skeletal formula of a fused polycyclic system with two carbonyls, one N H and wedge stereobonds.Inhibiting TGF-β1[130] Table 2Alkaloids with Improved Renal Fibrosis FunctionActive ConstituentsStructural FormsMechanismsReferencesBerberineLine-angle skeletal formula of a fused polycyclic ring system with two methoxy groups and N plus.Inhibiting TGF-β/Smad, NF-κB, Notch/snail, Suppressing the NLRP3 inflammasome, Activating RhoA/ROCK[119–121,124,125]Matrine2D line-bond diagram of a fused three-ring system with two N atoms and one C double bond O group.Decreasing TIMP-1 and FN, and increasing MMP-3[126]OxymatrineLine-angle skeletal structure of a fused three-ring system with two nitrogens, one carbonyl and N plus.Upregulating SnoN and inhibiting TGF-β1/Smad[122]SinomenineLine-angle structure of a fused-ring molecule with hydroxyl, methoxy, carbonyl and tertiary amine groups.Inhibiting autophagy, Activating Nrf2 and inhibiting TGF-β[123,127]ColchicineUnlabeled skeletal structure of a fused four-ring polycyclic compound with methoxy and multiple carbonyl groups.Inactivating RhoA[128]CaffeineA two-dimensional line-bond structure of a fused six-membered and five-membered ring with four N and two C O.Activating Nrf2 signaling and suppressing Snail1[129]Evodiamine2D skeletal formula of a fused polycyclic system with two carbonyls, one N H and wedge stereobonds.Inhibiting TGF-β1[130] Alkaloids with Improved Renal Fibrosis Function Terpenoids Terpenoids can be divided into monoterpenes, sesquiterpenes, diterpenes, triterpenes, and polyterpenes depending on their chemical structure. These compounds have diverse pharmacological activities, such as anti-inflammatory, blood glucose regulatory, anti-cancer, and anti-fibrosis activities (Table 3). Both dihydroartemisinin and triptolide have been proven to have the effect of improving renal fibrosis. Triptolide is a triterpenoid isolated from Tripterygium wilfordii with immunomodulatory and anti-inflammatory activities. In 2015, Cao et al found that triptolide can exert renal protective effects by inhibiting TGF-β1 induced mesangial cell proliferation, downregulating Smad3 related mRNA and protein expression.131 In 2017, Li et al reported that triptolide could restore autophagy inhibition caused by overexpression of miR-141-3p and alleviate renal fibrosis.132 In addition, studies have shown that triptolide can inhibit the infiltration of renal interstitial mononuclear/macrophage cells, alleviate renal tubulointerstitial injury and fibrosis, and further alleviate renal damage caused by acetic acid deoxycorticosterone salt-induced hypertension.133 Table 3Terpenoids with Improved Renal Fibrosis FunctionActive ConstituentsStructural FormsMechanismsReferencesTriptolideLine-angle structure of a polycyclic lactone with hydroxyl groups and stereochemistry indicated by wedge bonds.Down-regulating Smad3 mRNA, miR-141-3p, Inhibiting monocyte/macrophage-mediated inflammatory responses[131–133]CrocinSymmetrical polyene with sugar-linked rings and conjugated double bonds.Inhibiting NLRP3 inflammasomes[134]Ursolic acidSkeletal line-angle formula of an unlabeled steroid-like fused tetracyclic framework with O H and C double bond O.Inhibiting TGF-β/Smad. Activating Nrf2/HO-1[135,136]Oleanolic acidA two-dimensional skeletal steroid with four fused rings, three hydroxyl groups and one carbonyl group.Inhibiting TGF-β/Smad, Reducing oxidative stress and reducing endoplasmic reticulum stress[137–139]CelastrolA two-dimensional skeletal formula of a fused-ring steroid with one aromatic ring, two hydroxyls, two carbonyls.Upregulating cannabinoid receptor 2[140]ArtemisininSkeletal structure of a polycyclic compound with carbonyl, ether and stereochemistry.Promoting AKT phosphorylation and Nrf2 nuclear translocation[141]Paclitaxel2D skeletal formula of a polycyclic molecule with amide, carbonyl, hydroxyl groups and stereochemistry.Inhibiting STAT3, Suppressing TGF-β[142,143]Pomolic acidLine-angle steroid with four fused rings, three hydroxyl groups, one ketone and an Ac label.Inhibiting SMAD-STAT[144]Asiatic acidLine-angle steroid with four fused rings, five hydroxyl groups and wedge dash stereochemistry.Improving the TFEB-mediated autophagy-lysosome, Promoting the production of 15d-PGJ2, Inhibiting TGF-β1[145–147] Table 3Terpenoids with Improved Renal Fibrosis FunctionActive ConstituentsStructural FormsMechanismsReferencesTriptolideLine-angle structure of a polycyclic lactone with hydroxyl groups and stereochemistry indicated by wedge bonds.Down-regulating Smad3 mRNA, miR-141-3p, Inhibiting monocyte/macrophage-mediated inflammatory responses[131–133]CrocinSymmetrical polyene with sugar-linked rings and conjugated double bonds.Inhibiting NLRP3 inflammasomes[134]Ursolic acidSkeletal line-angle formula of an unlabeled steroid-like fused tetracyclic framework with O H and C double bond O.Inhibiting TGF-β/Smad. Activating Nrf2/HO-1[135,136]Oleanolic acidA two-dimensional skeletal steroid with four fused rings, three hydroxyl groups and one carbonyl group.Inhibiting TGF-β/Smad, Reducing oxidative stress and reducing endoplasmic reticulum stress[137–139]CelastrolA two-dimensional skeletal formula of a fused-ring steroid with one aromatic ring, two hydroxyls, two carbonyls.Upregulating cannabinoid receptor 2[140]ArtemisininSkeletal structure of a polycyclic compound with carbonyl, ether and stereochemistry.Promoting AKT phosphorylation and Nrf2 nuclear translocation[141]Paclitaxel2D skeletal formula of a polycyclic molecule with amide, carbonyl, hydroxyl groups and stereochemistry.Inhibiting STAT3, Suppressing TGF-β[142,143]Pomolic acidLine-angle steroid with four fused rings, three hydroxyl groups, one ketone and an Ac label.Inhibiting SMAD-STAT[144]Asiatic acidLine-angle steroid with four fused rings, five hydroxyl groups and wedge dash stereochemistry.Improving the TFEB-mediated autophagy-lysosome, Promoting the production of 15d-PGJ2, Inhibiting TGF-β1[145–147] Terpenoids with Improved Renal Fibrosis Function The Main Barrier for Drug Delivery in Renal Fibrosis The systemic circulation barrier, glomerular filtration, renal tubular reabsorption and clearance, and extracellular matrix deposition are the main barriers to drug delivery during renal fibrosis. These challenges affect both small-molecule drugs and nanoparticle-based (NPs)-based delivery systems at various stages, ultimately hindering effective drug delivery. The systemic barrier affects the in vivo fate of both free drugs and NPs, whereas glomerular filtration, tubular reabsorption and clearance, and ECM deposition determine their accumulation in the fibrotic target cells. Systemic Circulation Barrier Systemic circulation from the site of administration is an important route for drugs to reach various tissues and organs throughout the body. Non-targeted small-molecule drugs are randomly distributed in various tissues and organs, and have a short circulation time in the body. NPs can regulate the pharmacokinetics and biological distribution of drug payloads to increase the drug concentration in target tissues and reduce systemic side effects. NPs used for drug delivery may undergo changes in their physical or chemical properties during the systemic circulation. After entering the systemic circulation, NPs may migrate to macrophages in the liver, lymph nodes, and spleen, or to macrophages (Kupffer cells) residing in the hepatic sinuses.148 In the vascular chamber, serum proteins may adsorb these NPs to form a “protein corona,” which is related to their particle size and charge.149 The formation of a protein corona in NPs is crucial for their subsequent fate, which may lead to an increase in particle size and hydrodynamic diameter (HD).150 In addition, HD is directly related to the blood circulation time and half-life. Glomerular Filtration Renal corpuscles and tubules constitute the functional units of the kidneys. The renal corpuscle contains a cluster of capillaries and supporting tissue known as the glomerulus. Blood reaches the kidneys through the afferent arterioles and glomeruli, and then flows out through the efferent arterioles. The glomerular filtration barrier consists of three layers: glomerular endothelial fenestration (approximately 100 nm), GBM (300 nm thick, 3 nm pore size), and podocyte filtration pores (approximately 32 nm).151–153 Under healthy conditions, solutes and molecules with an HD of less than 5–7 nm can pass through this barrier.154 Small-molecule drugs and their metabolites are precisely excreted, while most therapeutic NPs are 30–150 nm and it is difficult to enter urine through glomerular filtration unless they degrade to<10 nm or the glomerular barrier is damaged by the disease. Owing to the negative charge of the glomerular filtration barrier, negatively charged proteins and NPs are rejected in a healthy state. The glomerular barrier in patients with kidney disease may rupture due to the expansion of the endothelial gap.155 Therefore, particle size and charge are key factors limiting renal allocation in drug delivery systems. Renal Tubular Resorption and Clearance Besides glomerular filtration, tubular reabsorption and secretion are important processes in renal excretion.156 Small molecule drugs or NPs that pass through GFB are easily reabsorbed into the bloodstream or excreted with urine, making it difficult for them to remain in large quantities at the fibrotic site of the tubulointerstitial tissue.157 Proximal renal tubular cells secrete transporters, mainly including uptake transporters (such as organic anion transporters and organic cation transporters) and efflux transporters (such as P-glycoprotein). The uptake transporter is the main mediator for drugs and NPs to enter renal tubular cells. However, this requires nanoparticles to be able to bind to transporters and have a particle size of 1–5 nm.158 ECM Deposition Within the renal fibrosis niche, a dense ECM network forms a spatial barrier that severely restricts the penetration of deep NPs. An imbalance between ECM secretion and degradation leads to excessive matrix protein accumulation, which entraps the cells within the fibrotic microenvironment. NPs that reach the extracellular space are sequestered by the ECM barrier, severely limiting their interactions with target cells.159 Therefore, effective strategies to overcome the ECM barrier are essential for enhancing the drug delivery efficiency. One promising approach involves engineering NPs capable of locally degrading the ECM, which can reduce their structural density and promote NP uptake by target cells. Surface modification of nanoparticles with ECM-degrading enzymes enhances their ability to penetrate this barrier and reach target cells. Targeted Drug Delivery Systems for Renal Fibrosis Currently, achieving an adequate drug concentration at the lesion site is a significant challenge in the treatment of renal fibrosis. Therefore, researchers have attempted to identify effective strategies for drug delivery to renal target cells (Tables 4 and 5). Based on a detailed understanding of the renal structure and pathogenesis of renal fibrosis, finding clear molecular targets is crucial for designing drug delivery systems. Liposomes, nanoparticles, extracellular vesicles (EVs), antibody-drug conjugates, and mesenchymal stem cells (MSCs) are the most commonly used drug delivery systems for treating renal fibrosis. Myofibroblasts and proximal tubular epithelial cells are specifically targeted for drug delivery in the treatment of renal fibrosis. Table 4Recent Studies on Drug Delivery Systems for the Treatment of Renal FibrosisNanoparticlesMicelle-hydrogel hybridNanoemulsionNanocomplexCoordination nanocomplexLiposomespH-responsive nanoparticleMicrovesicle (Named MV-DEX)Liposome-Nanoparticle HybridsHost-guest supramolecular hydrogelVirus-Mimetic NanoparticlesNanomedicineLipoprotein nanoparticlesEntrappedcomponentsCelastrolDexamethasoneERS inhibitor Ceapin 7DoxorubicinSalvianolic acid BCelastrolDinitrosyl iron complexDexamethasoneDexamethasone and CaptoprilmiR-29bCinaciguatNintedanibTriptolideNintedanibCarrier materialBis-F127-methacrylateE80, MCTCatechol-derived low molecular weight chitosanCatechol-derived low molecular weight chitosanLipoid S100PEG-PDPA, TPGSMacrophage-derived microvesicleSoy lecithin, Cholesterol, TPGS, PLGAβ-CD, F127, AdamantanePEG-PLA, PLGAFatty acid-peptide conjugateDMPCParticle size(nm)/Zeta potential (mv)35.6–0.13±0.011161±20.3–26.938.5±4.366.8±0.5111.6± 1.520.33±0.4259.67±0.58−5.00±1.48140.7±4.8119.1±2.31−10.1±0.2212±118±0.496142.85±1.4510.9EncapsulationEfficiency (%)>9088.5±13.296.2±12.3––94.45 ± 4.18––––56.6459.1084.7897.7References[160][161][162][163][164][165][166][85][167][168][169][170] Table 5The Therapeutic Mechanism of the Existing Drug Delivery SystemsNanoparticlesMicelle-hydrogel hybridNanoemulsionNanocomplexCoordination nanocomplexLiposomespH-responsive nanoparticleMicrovesicle (Named MV-DEX)Liposome-Nanoparticle HybridsHost-guest supramolecular hydrogelVirus-Mimetic NanoparticlesNanomedicineLipoprotein nanoparticlesTarget cellsMacrophagesMacrophagesRenal tubular epithelial cellsRenal tubular epithelial cellsMyofibroblastsMyofibroblastsGlomerular endothelial cellsGlomerular endothelial cellsRenal tubular epithelial cellsMesangial cellsRenal tubular epithelial cellsRenal tubular epithelial cellsTargeting principleLocal injectionTargeting fibronectin with DSPE-PEG-CREKA and endoplasmic reticulum with DSPE-PEG-PadaxinCatechol-derived chitosan binded specifically to megalin on the surface of tubular epithelial cellsCatechol-derived chitosan binded specifically to megalin on the surface of tubular epithelial cellsTargeting fibronectin with DSPE-PEG-CREKApH responsive releaseRAW 264.7 macrophage cell-derived MVs be used as vectors to targeting the inflamed kidneyActive targeting based on α8 integrin antibody modificationLocalized deliveryVirus-Mimetic mediatedNanoparticles modified with LRG1 specific recognition peptidesNanoparticles modified with KIM-1 specific ligandsTherapeutic targetsNF-κB, TGF-β1TGF-β–TGF-β1TGF-β1–NF-κBTGF-βTGF-β1TGF-βTGF-β1-Therapeutic efficacyInhibited NF-κB signaling pathway and TGF-β1Calibrated the level of TGF-β, Suppressed MMTSignificantly reduced renal fibrosisReversed renal fibrosisInhibited the activation of myofibroblasts70% of the fibrotic area was reducedSuppressed renal inflammation and fibrosisReduced expression of inflammatory factors, fibrotic factors, and ROSDelayed and reversed renal interstitial fibrosisSuppressed the TGF-β pathwayInhibited TGF-β1, mitigated renal fibrosisRemodeled the fibrotic nichesReferences[160][161][162][163][164][165][166][85][167][168][169][170] Table 4Recent Studies on Drug Delivery Systems for the Treatment of Renal FibrosisNanoparticlesMicelle-hydrogel hybridNanoemulsionNanocomplexCoordination nanocomplexLiposomespH-responsive nanoparticleMicrovesicle (Named MV-DEX)Liposome-Nanoparticle HybridsHost-guest supramolecular hydrogelVirus-Mimetic NanoparticlesNanomedicineLipoprotein nanoparticlesEntrappedcomponentsCelastrolDexamethasoneERS inhibitor Ceapin 7DoxorubicinSalvianolic acid BCelastrolDinitrosyl iron complexDexamethasoneDexamethasone and CaptoprilmiR-29bCinaciguatNintedanibTriptolideNintedanibCarrier materialBis-F127-methacrylateE80, MCTCatechol-derived low molecular weight chitosanCatechol-derived low molecular weight chitosanLipoid S100PEG-PDPA, TPGSMacrophage-derived microvesicleSoy lecithin, Cholesterol, TPGS, PLGAβ-CD, F127, AdamantanePEG-PLA, PLGAFatty acid-peptide conjugateDMPCParticle size(nm)/Zeta potential (mv)35.6–0.13±0.011161±20.3–26.938.5±4.366.8±0.5111.6± 1.520.33±0.4259.67±0.58−5.00±1.48140.7±4.8119.1±2.31−10.1±0.2212±118±0.496142.85±1.4510.9EncapsulationEfficiency (%)>9088.5±13.296.2±12.3––94.45 ± 4.18––––56.6459.1084.7897.7References[160][161][162][163][164][165][166][85][167][168][169][170] Recent Studies on Drug Delivery Systems for the Treatment of Renal Fibrosis Table 5The Therapeutic Mechanism of the Existing Drug Delivery SystemsNanoparticlesMicelle-hydrogel hybridNanoemulsionNanocomplexCoordination nanocomplexLiposomespH-responsive nanoparticleMicrovesicle (Named MV-DEX)Liposome-Nanoparticle HybridsHost-guest supramolecular hydrogelVirus-Mimetic NanoparticlesNanomedicineLipoprotein nanoparticlesTarget cellsMacrophagesMacrophagesRenal tubular epithelial cellsRenal tubular epithelial cellsMyofibroblastsMyofibroblastsGlomerular endothelial cellsGlomerular endothelial cellsRenal tubular epithelial cellsMesangial cellsRenal tubular epithelial cellsRenal tubular epithelial cellsTargeting principleLocal injectionTargeting fibronectin with DSPE-PEG-CREKA and endoplasmic reticulum with DSPE-PEG-PadaxinCatechol-derived chitosan binded specifically to megalin on the surface of tubular epithelial cellsCatechol-derived chitosan binded specifically to megalin on the surface of tubular epithelial cellsTargeting fibronectin with DSPE-PEG-CREKApH responsive releaseRAW 264.7 macrophage cell-derived MVs be used as vectors to targeting the inflamed kidneyActive targeting based on α8 integrin antibody modificationLocalized deliveryVirus-Mimetic mediatedNanoparticles modified with LRG1 specific recognition peptidesNanoparticles modified with KIM-1 specific ligandsTherapeutic targetsNF-κB, TGF-β1TGF-β–TGF-β1TGF-β1–NF-κBTGF-βTGF-β1TGF-βTGF-β1-Therapeutic efficacyInhibited NF-κB signaling pathway and TGF-β1Calibrated the level of TGF-β, Suppressed MMTSignificantly reduced renal fibrosisReversed renal fibrosisInhibited the activation of myofibroblasts70% of the fibrotic area was reducedSuppressed renal inflammation and fibrosisReduced expression of inflammatory factors, fibrotic factors, and ROSDelayed and reversed renal interstitial fibrosisSuppressed the TGF-β pathwayInhibited TGF-β1, mitigated renal fibrosisRemodeled the fibrotic nichesReferences[160][161][162][163][164][165][166][85][167][168][169][170] The Therapeutic Mechanism of the Existing Drug Delivery Systems Drug Delivery Systems Targeting Glomerulus The glomerulus is a blood filter, and glomerular filtration rate is an important indicator of renal function. The glomerulus is composed of glomerular endothelial cells (GEC), GBM, podocytes, mesangial cells, and parietal epithelial cells.171–174 Glomerular injury is the major cause of renal fibrosis. The targeted delivery of drugs to the glomerulus is an important strategy for improving chronic kidney disease and renal fibrosis. The initial delivery targeting the glomerulus focused on the delivery of immunosuppressants through liposomes. For example, in 2001, Liao et al developed liposomes containing prednisolone phosphate for the treatment of immunoglobulin deposition nephropathy.175 In 2008, Scindia et al prepared anti-α8 integrin immunoliposomes for the treatment of systemic lupus erythematosus nephropathy based on the principle of high expression of α8 integrin on the surface of glomerular mesangial cells.176 Another approach is to target the delivery of immunosuppressants to podocytes for the treatment of proteinuria. Faul et al demonstrated that the actin cytoskeleton of renal podocytes is a direct target of the antiproteinuric effect.177 Recently, delivery strategies using plant ingredients have been developed for the treatment of chronic kidney disease and renal fibrosis. In 2021, Wu et al used phospholipid lipid nanoparticles (PC-PLNs) to deliver celastrol to glomerular endothelial cells and podocytes, achieving an effective treatment of chronic kidney disease (Figure 3A).178 The nanoparticles loaded with DID (D-PLNs) were mainly distributed in the glomerulus, whereas only weak self-fluorescence was detected in the tubular region (Figure 3B). The nanoparticles significantly reduced the levels of creatinine and urea in CKD model mice (Figure 3C). In addition, nanoparticles with higher positive charges (Hpos-D-PLNs) were more likely to recruit glomeruli (Figure 3D). Figure 3Targeting glomerular endothelial cells and podocytes for the treatment of chronic kidney disease. (A) Schematic representation of PC-PLNs for treating CKD. (B) Representative confocal images of D-PLNs localization at kidney. (C(i)) The serum levels of Crea and (C(ii)) Urea in CKD mice. (D(i)) PLNs zeta-dependently accumulate in MPC5 cells and (D(ii)) in MRGEC cells. *P < 0.05; ***P < 0.001; ****P < 0.0001; #P < 0.05; ###P < 0.001; ####P < 0.0001. Nano Res. 2022;15, 3556–3568.178Composite image showing PC-PLNs targeting CKD treatment, confocal images, serum levels and PLN accumulation.The composite image consists of four parts. A shows a schematic of PC-PLNs targeting injury cells in mice, highlighting celastrol's role in alleviating injury. B presents confocal images of D-PLNs localization in kidney tubules and glomeruli, with DID, DAPI and merged views. C displays graphs of serum levels of creatinine (Crea) and urea in CKD mice, comparing NT, blank, Free CLT, NC-PLNs, C-PLNs and PC-PLNs treatments. D includes confocal images of PLN accumulation in MPC5 and MRGEC cells, with DID, PODXL, ESMI, DAPI and merged views, comparing Neg-D-PLNs, Neu-D-PLNs, Pos-D-PLNs and HPos-D-PLNs. Statistical significance is indicated with asterisks: less than 0.05, less than 0.001, less than 0.0001.Abbreviation: ns, not significant. Targeting glomerular endothelial cells and podocytes for the treatment of chronic kidney disease. (A) Schematic representation of PC-PLNs for treating CKD. (B) Representative confocal images of D-PLNs localization at kidney. (C(i)) The serum levels of Crea and (C(ii)) Urea in CKD mice. (D(i)) PLNs zeta-dependently accumulate in MPC5 cells and (D(ii)) in MRGEC cells. *P < 0.05; ***P < 0.001; ****P < 0.0001; #P < 0.05; ###P < 0.001; ####P < 0.0001. Nano Res. 2022;15, 3556–3568.178 Drug Delivery Systems Targeting Proximal Tubular Epithelial Cells Anatomically, proximal tubular epithelial cells are the largest component of renal tubules and play an important role in the reabsorption of urine.179 Activated proximal tubular epithelial cells secrete cytokines that promote inflammation or interstitial damage to the renal tubules, exacerbating the formation and development of fibrosis, and even causing glomerulosclerosis.180,181 The delivery strategy targeting the proximal epithelial tubules can maximize the therapeutic effect of drugs and alleviate renal fibrosis. Water-soluble polymers, proteins, and peptides are commonly used as carrier materials for targeting proximal tubular epithelial cells.182 For example, the 1:1 complex of megalin and cubilin is located on the apical plasma membrane of proximal tubular epithelial cells and can mediate endocytosis of certain small-molecule proteins.183 Lysozyme and polymyxin B (PMX-B) have good affinity for megalin. Prakash et al inhibited the activation of proximal tubular epithelial cells in a unilateral ureteral obstruction (UUO) rat model by coupling lysozyme with a T-type receptor (TKI) through platinum-based ligands, thereby inhibiting renal fibrosis.184 Dolman et al linked sunitinib analogs (named 17864) to lysozyme through platinum-based ligands and found that 17864 lysozyme conjugates rapidly accumulated in the kidneys and exerted anti-fibrotic effects.185 In recent years, the delivery strategy for targeting renal tubules to treat diabetic nephropathy has also made some progress. Chen et al realized the effective treatment of diabetic nephropathy through rhein-loaded polyethyleneglycol-co-polycaprolactone-co-polyethylenimine nanoparticles.186 Biomimetic high-density lipoprotein nanoparticles exhibit ultrasmall particle size, which is a key characteristic that enables them to effectively penetrate the glomerular filtration barrier and reach renal tubular epithelial cells. He et al constructed biomimetic high-density lipoprotein liposomes (TP/BIBF bHDL) loaded with Triptolide and Nidanib to spontaneously target damaged renal tubules and alleviate renal fibrosis by reshaping the fibrotic niche (Figure 4A).170 This biomimetic liposome can be taken up by HK-2 cells damaged by cisplatin at 2 hours (Figure 4B). After injection into a mouse model of unilateral ureteral obstruction (UUO) through the tail vein, we found that biomimetic liposomes loaded with Did had a higher recruitment rate in the kidneys (Figure 4C). Western blot analysis showed that biomimetic liposomes reduced the content of α-SMA in fibrotic kidneys (Figure 4D). Immunohistochemical experiments showed that biomimetic liposomes reduced the deposition of the extracellular matrix and the release of inflammatory factors (Figure 4E). HE and Masson’s trichrome staining of kidney tissue slices showed that biomimetic liposomes attenuated kidney injury and collagen deposition in fibrotic kidneys (Figure 4F). Figure 4High-density lipoprotein nanoparticles spontaneously target to damaged renal tubules and alleviate renal fibrosis by remodeling the fibrotic niches. (A) Schematic illustration of TP/BIBF-bHDL preparation and KIM-1 mediated targeting of bHDL nanoparticles to injured renal tubules for CKD treatment. (B) Representative confocal images of cisplatin-injured HK-2 cells after 2 hours of exposure. (C) Bioluminescence images of major organs in UUO mice after intravenous administration of DiD, DiD-liposome or DiD-bHDL. (D) Western blot images of α-SMA. (E) Representative immunohistochemical images for COL1A1, α-SMA, F4/80, CD3, TNF-α and IL-1β in the kidney of UUO mice with different treatments. (F) HE and Masson staining of kidney tissues of UUO mice after different treatments. Nat. Commun. 2025;16, 1061.170An infographic showing TP/BIBF-bHDL kidney targeting and reduced fibrosis markers in a UUO model.The image A showing an infographic schematic of TP/BIBF-bHDL preparation and targeting to injured renal tubules via KIM-1, with labels DMPC, Triptolide, Nintedanib, TP/BIBF-bHDL and DiD. The kidney diagram labels Fibrotic kidney, Nephron and Proximal tubule. The tubule schematic includes labels Tubule lumen, Tubule damage, Endocytosis, Renal tubular epithelial cells, Interstitium, Inflammatory cytokines, Fibroblast activation, Myofibroblast, Remodel fibrotic niche, Immune cell infiltration, ECM deposition and Blood stream. The image B showing confocal and microscopy views labeled DiD-bHDL, KIM-1, DAPI, Bright field and Merge, with a scale bar 20 micrometer. The image C showing organ bioluminescence images labeled Heart, Liver, Spleen, Kidney, Lung, Brain, comparing DiD, DiD-Liposome and DiD-bHDL at 6h and 24h; kidney signal appears higher for DiD-bHDL than DiD and DiD-Liposome. The image D showing western blot bands in a UUO model with lanes labeled Control, PBS, TP/BIBF and TP/BIBF-bHDL; rows labeled alpha-SMA 42 kDa and alpha-tubulin 55 kDa; alpha-SMA bands appear lower for TP/BIBF-bHDL than PBS. The image E showing immunohistochemical grids under UUO with columns Control, PBS, TP, BIBF, TP/BIBF, TP-bHDL, BIBF-bHDL and TP/BIBF-bHDL; rows labeled COL1A1, alpha-SMA, F4/80, CD3, TNF-alpha and IL-1beta; staining appears reduced in TP/BIBF-bHDL compared with PBS for multiple markers. Scale bar 40 micrometer. The image F showing kidney histology in a UUO Model with columns Control, PBS, TP/BIBF and TP/BIB-bHDL; rows labeled HE and Masson; tissue appearance differs across groups, with less prominent fibrotic staining in TP/BIB-bHDL than PBS. Scale bar 50 micrometer. High-density lipoprotein nanoparticles spontaneously target to damaged renal tubules and alleviate renal fibrosis by remodeling the fibrotic niches. (A) Schematic illustration of TP/BIBF-bHDL preparation and KIM-1 mediated targeting of bHDL nanoparticles to injured renal tubules for CKD treatment. (B) Representative confocal images of cisplatin-injured HK-2 cells after 2 hours of exposure. (C) Bioluminescence images of major organs in UUO mice after intravenous administration of DiD, DiD-liposome or DiD-bHDL. (D) Western blot images of α-SMA. (E) Representative immunohistochemical images for COL1A1, α-SMA, F4/80, CD3, TNF-α and IL-1β in the kidney of UUO mice with different treatments. (F) HE and Masson staining of kidney tissues of UUO mice after different treatments. Nat. Commun. 2025;16, 1061.170 In 2024, Zhang et al designed LRG1 targeted nanoparticles to deliver nintedanib to fibrotic tubular epithelial cells, effectively reducing the expression of the extracellular matrix and organizing the progression of fibrosis (Figure 5A).169 Cell uptake experiments showed that nanoparticles (DENNM-Cy5) can be effectively taken up by HK-2 cells induced by TGF-β1 (Figure 5B). In addition, Cy5 loaded nanoparticles exhibit stronger fluorescence in blocked kidneys and significantly colocalized with the green fluorescence of the fibrosis target (LRG1), thereby confirming the targeting efficacy of DENNM in UUO-induced renal fibrosis (Figure 5C). Ex vivo kidneys imaging demonstrated a significant reduction in renal pallor in mice treated with nintedanib-containing nanomedicine (Figure 5D). Figure 5LRG1-targeted nintedanib delivery for enhanced renal fibrosis mitigation. (A) Schematic representation of DENNM-mediated attenuation of renal fibrosis. (B) Cellular uptake of DENNM and its anti-fibrosis assessment in vitro. (C) Fluorescence images of tissue sections from obstructed- or sham-operated kidneys derived from mice with different treatments. Cell nucleus were stained in blue, and LRG1 was stained in green. (D) Representative images of ex vivo kidneys from mice receiving different treatments. Nano Lett. 2024;24, 11097–11107. Copyright © 2024, American Chemical Society.169Composite figure: schematic, cell microscopy, tissue fluorescence and ex vivo kidney images.The image consists of four sections: A illustrates nanoparticle self-assembly targeting damaged renal cells, showing accumulation in kidneys post-obstruction, LRG1 targeting, Caspase-3 cleavage and nintedanib release to reduce fibronectin, Collagen I and alpha smooth muscle actin. B presents fluorescence microscopy of cells under four conditions: PBS, TGF beta 1 with DMNNM-Cy5, DENNM-Cy5 and TGF beta 1 with DENNM-Cy5, displaying bright field, Hoechst 33342 nucleus staining, Cy5 signal and merged views. The TGF beta 1 plus DENNM-Cy5 condition shows the strongest Cy5 uptake. C depicts tissue section fluorescence images from sham and obstructed kidneys treated with DMNNM-Cy5 or DENNM-Cy5, at 50 and 20 micrometer scales, with obstruction plus DENNM-Cy5 showing strong Cy5 signal colocalizing with LRG1. D displays ex vivo kidney photos across seven groups (G1-G7), with a 1 cm scale bar, highlighting differences in kidney size and appearance across treatments. LRG1-targeted nintedanib delivery for enhanced renal fibrosis mitigation. (A) Schematic representation of DENNM-mediated attenuation of renal fibrosis. (B) Cellular uptake of DENNM and its anti-fibrosis assessment in vitro. (C) Fluorescence images of tissue sections from obstructed- or sham-operated kidneys derived from mice with different treatments. Cell nucleus were stained in blue, and LRG1 was stained in green. (D) Representative images of ex vivo kidneys from mice receiving different treatments. Nano Lett. 2024;24, 11097–11107. Copyright © 2024, American Chemical Society.169 Drug Delivery Systems Targeting Myofibroblasts As mentioned earlier, myofibroblasts are the main source of ECM. Therefore, drug delivery targeting myofibroblasts is an important strategy to improve renal fibrosis. Many researchers have been dedicated to this work, and have achieved certain research results. Poosti et al prepared PEGylated IFN-γ conjugated to a PDGFR-β-recognizing peptide to treat renal fibrosis. This preparation can specifically recognize myofibroblasts expressing PDGFR-β, thus accumulating in fibrotic kidneys.187 Li et al designed a liposome that was coupled with a five peptide (CREKA) specifically binding to fibronectin to deliver triptolide to myofibroblasts. This type of liposome can be specifically internalized by myofibroblasts to improve renal fibrosis and reduce toxicity to other major organs.164 Xu et al prepared an antibody-drug conjugate IgG78-DM1 by linking maytansinoid (DM1) with the fully human antibody IgG78 through an uncleavable SMCC linker. They demonstrated that CD248 is expressed in myofibroblasts in the kidneys of CKD patients, and IgG78-DM1 has specific killing effects on CD248+ myofibroblasts.188 Cheng et al designed lipid-coated poly (lactic-co-glycolic acid) nanoparticles for delivering sorafenib, with renal fibrotic homing peptide on the surface (Figure 6A and B). Masson staining and immunofluorescence staining of α-SMA and Collagen I indicated reversal of renal fibrosis (Figure 6C). The quantitative analysis of α-SMA and Collagen I also confirmed this result (Figure 6D and E).189 Figure 6Delivery of sorafenib by myofibroblast-targeted nanoparticles for the treatment of renal fibrosis. (A) Screening of targeted peptides. (B) Scheme that shows the mechanism by which sorafenib loaded in fibrotic kidney-targeted NPs ameliorates renal fibrosis in mice. (C) Masson staining of kidney sections from UUO mice treated with different nanoparticles, as well as immunofluorescence staining of α-SMA and Collagen. (D) Collagen and (E) α-SMA expression in randomly selected fields within fibrotic kidneys. ***P < 0.001. J. Control Release. 2022;346, 169–179.189A composite image showing biopanning, nanoparticle design, kidney treatment and analysis of collagen and α-SMA.The image consists of multiple panels detailing various processes and analyses. A shows in vivo and in vitro biopanning using coll-GFP mice and human fibroblasts, involving phage peptide library and FACS. B illustrates the design of sorafenib-loaded nanoparticles with components like PLGA, cholesterol and fibrotic kidney-targeted peptide and their mechanism in treating UUO-induced fibrotic kidneys. C presents Masson staining and immunofluorescence staining of α-SMA and Collagen in different treatment groups: w/o UUO, Control, Free Sor, NT-NP, YQT12-NP, YQT38-NP and RDYH58-NP. D is a bar graph showing Collagen I expression in fibrotic kidney area percent across treatments, with significant differences marked by asterisks. E is a bar graph showing α-SMA expression in fibrotic kidney area percent, also highlighting significant differences. The scale bar in C is 50 micrometers. Delivery of sorafenib by myofibroblast-targeted nanoparticles for the treatment of renal fibrosis. (A) Screening of targeted peptides. (B) Scheme that shows the mechanism by which sorafenib loaded in fibrotic kidney-targeted NPs ameliorates renal fibrosis in mice. (C) Masson staining of kidney sections from UUO mice treated with different nanoparticles, as well as immunofluorescence staining of α-SMA and Collagen. (D) Collagen and (E) α-SMA expression in randomly selected fields within fibrotic kidneys. ***P < 0.001. J. Control Release. 2022;346, 169–179.189 Conclusions and Prospects The development and progression of renal fibrosis are intricate processes involving multiple signaling pathways and intracellular reactions. Significant progress has been made in the pathogenesis of renal fibrosis, with a deeper understanding of the “fibrotic niche,” especially the activation and proliferation of myofibroblasts, sources and composition of ECM networks, and related signaling pathways. Numerous key targets have been identified in renal fibrosis, and drug development targeting these multiple pathways has demonstrated success at both cellular and animal model levels. However, renal fibrosis therapy is limited by drug delivery challenges across the systemic circulation, glomerular filtration, renal tubules, and ECM penetration. TDDS has significantly enhanced the treatment effect of drugs by overcoming barriers to renal fibrosis. Given that glomeruli and renal tubules are the primary damaged structures in renal fibrosis, various drug delivery systems (eg, liposomes, chitosan nanoparticles, and extracellular vesicles) have been developed to target glomeruli, renal tubules, and activated myofibroblasts. Most strategies employ peptide- or protein-modified nanoparticles to achieve receptor-mediated endocytosis, whereas others harness the natural homing properties of EVs or MSCs to achieve tissue-specific accumulation. Alternatively, some strategies utilize the degradation of MMPs or collagen in the ECM to increase the ability of NPs to penetrate the target cells. While preclinical studies have demonstrated significant progress in TDDS for renal fibrosis, critical limitations, including targeting specificity, tissue permeability, cellular targeting accuracy, interstitial penetration capacity, carrier stability, biosafety profiles, and manufacturing scalability, continue to impede complete disruption of the self-perpetuating “fibrotic niche.” To address these challenges, we propose three synergistic research directions. (1) Particle size and charge are the main factors influencing the ability of drug delivery systems to reach the target area. Physicochemical optimization (eg, sub-100 nm particles with neutral/negative surface charge) should be prioritized to enhance glomerular barrier penetration. (2) The progression of renal fibrosis involves intricate crosstalk among diverse cell types (eg, myofibroblasts, inflammatory cells, and parenchymal cells), which limits the efficacy of single-cell-targeted drug delivery. Developing delivery systems capable of modulating intercellular communication (eg, paracrine signaling or physical contact) may enable holistic intervention in the fibrotic microenvironment, thereby improving therapeutic outcomes; (3) In addition, we believe that TDDS designed using the homing ability of endogenous substances such as EVs or MSCs has the potential to achieve precise targeting. We envision an intelligent delivery platform that integrates “improving delivery efficiency-regulating therapeutic targets-remodeling pathological microenvironment” - a paradigm shift toward effective clinical translation; (4) Constrained by challenges in preparation process, biocompatibility, stability, and targeting efficiency, TDDS have not yet achieved clinical translation. A comprehensive quality control system and well-defined pharmacokinetic characteristics are indispensable prerequisites for TDDS to advance towards clinical application.